var data={"title":"Overview of carbapenemase-producing gram-negative bacilli","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Overview of carbapenemase-producing gram-negative bacilli</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/contributors\" class=\"contributor contributor_credentials\">John Quale, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/contributors\" class=\"contributor contributor_credentials\">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/contributors\" class=\"contributor contributor_credentials\">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 07, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenem antibiotics have an important antibiotic niche in that they retain activity against the chromosomal cephalosporinases and extended-spectrum beta-lactamases found in many gram-negative pathogens [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The emergence of carbapenem-hydrolyzing beta-lactamases has threatened the clinical utility of this antibiotic class and brings us a step closer to the challenge of &quot;extreme drug resistance&quot; in gram-negative bacilli [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Issues related to carbapenemases will be reviewed here. Penicillinases and cephalosporinases are discussed in detail separately. (See <a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">&quot;Extended-spectrum beta-lactamases&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenemases are carbapenem-hydrolyzing beta-lactamases that confer resistance to a broad spectrum of beta-lactam substrates, including carbapenems. This mechanism is distinct from other mechanisms of carbapenem resistance such as impaired permeability due to porin mutations, although the susceptibility patterns for isolates with a carbapenemase and those with porin mutations can be identical.</p><p>The carbapenemases have been organized based on amino acid homology in the Ambler molecular classification system. Class A, C, and D beta-lactamases all share a serine residue in the active site, while Class B enzymes require the presence of zinc for activity (and hence are referred to as metallo-beta-lactamases). Classes A, B, and D are of greatest clinical importance among nosocomial pathogens.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Class A beta-lactamases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Class A beta-lactamases are characterized by their hydrolytic mechanisms that require an active-site serine at position 70 [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/4\" class=\"abstract_t\">4</a>]. These include penicillinases and cephalosporinases in the TEM, SHV, and CTX-M-type groups (which do not hydrolyze carbapenems), as well as additional groups that possess beta-lactamase (including carbapenemase) activity [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/1,5\" class=\"abstract_t\">1,5</a>]. (See <a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">&quot;Extended-spectrum beta-lactamases&quot;</a>.)</p><p>Class A beta-lactamases with carbapenemase activity may be encoded on chromosomes or plasmids. Chromosomally-encoded enzymes include SME (<em>Serratia marcescens </em>enzyme), NMC (non-metalloenzyme carbapenemase) and IMI (imipenem-hydrolyzing) beta-lactamases. SME have been recovered in a small number of <em>S. marcescens</em> isolates, while IMI and NMC have been identified among <em>Enterobacter</em> isolates [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/6-8\" class=\"abstract_t\">6-8</a>]. Plasmid-encoded enzymes include KPC (<em>Klebsiella pneumoniae</em> carbapenemase) and GES (Guiana extended spectrum). GES has been described in <em>Pseudomonas</em> <em>aeruginosa</em> and <em>K. pneumoniae </em>[<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/5,9-11\" class=\"abstract_t\">5,9-11</a>]. (See <a href=\"#H19876835\" class=\"local\">'Klebsiella pneumoniae carbapenemase (KPC)'</a> below.)</p><p class=\"headingAnchor\" id=\"H19876835\"><span class=\"h3\">Klebsiella pneumoniae carbapenemase (KPC)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most clinically important of the Class A carbapenemases is the <em>K. pneumoniae</em> carbapenemase (KPC) group. These enzymes reside on transmissible plasmids and confer resistance to most beta-lactams [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/9\" class=\"abstract_t\">9</a>]. Several different variants of KPC enzymes have been identified. Some of the variants hydrolyze beta-lactams at varying rates, which may contribute to different susceptibility profiles in KPC-producing bacteria when tested in vitro [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/12,13\" class=\"abstract_t\">12,13</a>]. KPC can be transmitted from <em>Klebsiella</em> to other genera, including <em>E. coli</em>, <em>P. aeruginosa</em>, <em>Citrobacter</em>, <em>Salmonella</em>, <em>Serratia</em>, and <em>Enterobacter</em> spp [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/14-19\" class=\"abstract_t\">14-19</a>]. Another carbapenemase, BKC-1, has been detected in rare clinical isolates of <em>K. pneumoniae</em> in Brazil [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/20\" class=\"abstract_t\">20</a>]. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Class B beta-lactamases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Class B beta-lactamases are also known as the metallo-beta-lactamases (MBLs), which are named for their dependence upon zinc for efficient hydrolysis of beta-lactams. As a result, MBLs can be inhibited by EDTA (an ion chelator); however, they are not inhibited by beta-lactamase inhibitors such as tazobactam, clavulanate, sulbactam, and avibactam. The first MBL, IMP-1, was described in Japan in 1991 [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/21\" class=\"abstract_t\">21</a>]. Subsequently, additional groups of acquired MBLs have been identified: IMP, VIM, GIM, SPM, and SIM. There are a number of variants within each MBL group (for example, there are more than 50 IMP variants within the IMP group) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,23\" class=\"abstract_t\">22,23</a>].</p><p>There are both naturally occurring and acquired MBLs. Naturally occurring MBLs are chromosomally encoded and have been described in <em>Aeromonas hydrophilia</em>, <em>Chryseobacterium </em>spp, and <em>Stenotrophomonas maltophilia</em> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22\" class=\"abstract_t\">22</a>]. Acquired MBLs consist of genes encoded on integrons residing on large plasmids that are transferable between both species and genera [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/4,24-29\" class=\"abstract_t\">4,24-29</a>]. In a hospital outbreak involving 62 patients (including 40 intensive care unit patients), for example, an MBL gene (<em>bla</em>-IMP-4) spread among seven different gram-negative genera (<em>Serratia</em>, <em>Klebsiella</em>, <em>Pseudomonas</em>, <em>Escherichia</em>, <em>Acinetobacter</em>, <em>Citrobacter</em>, and <em>Enterobacter</em>) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24,30\" class=\"abstract_t\">24,30</a>].</p><p class=\"headingAnchor\" id=\"H19877222\"><span class=\"h3\">New Delhi metallo-beta-lactamase (NDM-1)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Enterobacteriaceae isolates carrying a novel MBL gene, the New Delhi metallo-beta-lactamase (NDM-1), were first described in December 2009 in a Swedish patient hospitalized in India with an infection due to <em>K. pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/31\" class=\"abstract_t\">31</a>]. </p><p>The gene encoding this MBL is located in a very mobile genetic element, and the pattern of spread appears to be more complex and more unpredictable than that of the gene encoding KPC [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/31,32\" class=\"abstract_t\">31,32</a>]. Furthermore, the large number of resistance determinants in the isolates studied raise concern that this gene is an important emerging resistance trait [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/33\" class=\"abstract_t\">33</a>]. In general, bacteria containing NDM-1 have tested susceptible to <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> or <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, though such susceptibility may be short-lived. </p><p>In addition to <em>K. pneumoniae</em>, NDM-1 has also been identified in other Enterobacteriaceae (including <em>E. coli</em> and <em>Enterobacter cloacae</em>) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/34\" class=\"abstract_t\">34</a>] as well as non-Enterobacteriaceae (including <em>Acinetobacter</em>) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Class D beta-lactamases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Class D beta-lactamases are also referred to as OXA-type enzymes because of their preferential ability to hydrolyze <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> (rather than penicillin) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/36\" class=\"abstract_t\">36</a>]. Enzymes in this group are variably affected by the beta-lactamase inhibitors clavulanate, sulbactam, or tazobactam. OXA carbapenemases have been identified in <em>Acinetobacter baumannii</em> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/36-45\" class=\"abstract_t\">36-45</a>] and Enterobacteriaceae (especially <em>K. pneumoniae</em>, <em>E. coli</em>, and <em>E. cloacae</em>) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/46\" class=\"abstract_t\">46</a>]. </p><p>Among the heterogeneous OXA group (which includes more than 100 enzymes), six subgroups have been identified with varying degrees of carbapenem-hydrolyzing activity: OXA-23, <span class=\"nowrap\">OXA-24/OXA40,</span> OXA-48, OXA-58, OXA-143, and OXA-51 (<a href=\"image.htm?imageKey=ID%2F56259\" class=\"graphic graphic_table graphicRef56259 \">table 1</a>). The first five groups are carried on transmissible plasmids, while the last group, OXA-51, is chromosomally encoded. While most isolates of <em>A. baumannii</em> possessing an OXA-23, <span class=\"nowrap\">-24/40,</span> or -58 type carbapenemase are resistant to carbapenems, Enterobacteriaceae with OXA-48-type enzymes have variable susceptibility to these agents. Expression of a promoter insertion element (ISAba1) in OXA-23 and OXA-51 likely contributes to carbapenem resistance [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H21045519\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H92008072\"><span class=\"h2\">Distribution</span></p><p class=\"headingAnchor\" id=\"H92008083\"><span class=\"h3\">Klebsiella pneumoniae carbapenemases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The <em>K. pneumoniae</em> carbapenemase (KPC) is the most common carbapenemase in the United States. Following the first description of KPC from a clinical isolate of <em>K. pneumoniae </em>in the late 1990s in North Carolina [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/9,47\" class=\"abstract_t\">9,47</a>], KPC-production has been identified in isolates from nearly every state, as of 2015 [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/48\" class=\"abstract_t\">48</a>]. In a surveillance study from sites in seven states from 2012 to 2013, the incidence of carbapenem-resistant Enterobacteriaceae isolates from urine or a sterile site was 2.93 cases per 100,000 person years; approximately half of the submitted isolates possessed the KPC beta-lactamase [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/49\" class=\"abstract_t\">49</a>].</p><p>In 2011, an outbreak of carbapenem-resistant <em>K. pneumoniae </em>occurred at the US National Institutes of Health Clinical Center that affected 18 patients, 11 of whom died [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/50\" class=\"abstract_t\">50</a>]. The CDC reported that the proportion of Enterobacteriaceae that were carbapenem resistant increased from 1 to 4 percent between 2001 and 2011; the proportion of carbapenem-resistant <em>Klebsiella</em> increased from 2 to 10 percent [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/51\" class=\"abstract_t\">51</a>]. Los Angeles County noted 675 cases of carbapenem-resistant <em>K. pneumoniae </em>between June 2010 and May 2011; the incidence was higher in long-term acute care facilities than in acute care hospitals [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/52\" class=\"abstract_t\">52</a>]. </p><p>KPC-possessing isolates have also been increasingly recovered from other regions of the world, including Europe [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/53,54\" class=\"abstract_t\">53,54</a>], Asia [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/14,55,56\" class=\"abstract_t\">14,55,56</a>], Australia [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/57\" class=\"abstract_t\">57</a>], and South America [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/15,58\" class=\"abstract_t\">15,58</a>]. </p><p class=\"headingAnchor\" id=\"H92008117\"><span class=\"h3\">Metallo-beta-lactamases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Metallo-beta-lactamases (MBLs) were initially described in Japan in 1991 [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/21\" class=\"abstract_t\">21</a>]. MBLs have since been described in other parts of Asia, Europe, North America, South America, and Australia [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,59-63\" class=\"abstract_t\">22,59-63</a>]. The transfer of patients between hospitals and the increase in international travel may be important factors in the geographical dissemination of MBL genes [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,28,59,64,65\" class=\"abstract_t\">22,28,59,64,65</a>]. </p><p>The MBL gene, the New Delhi metallo-beta-lactamase (NDM-1), was first described in December 2009 in a <em>K. pneumoniae </em>isolate from a Swedish patient who had been hospitalized in India [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/31\" class=\"abstract_t\">31</a>]. Subsequent reports have included patients who have traveled and undergone procedures (so called &quot;medical tourism&quot;) in India and Pakistan [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/34\" class=\"abstract_t\">34</a>], as well as cases reported in Asia, Europe, North America, the Caribbean, and Australia [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/32,34,66-69\" class=\"abstract_t\">32,34,66-69</a>].</p><p>In the United States, between January 2009 and February 2011, seven Enterobacteriaceae isolates with NDM-1 production were reported to the Centers for Disease Control and Prevention (CDC) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/68\" class=\"abstract_t\">68</a>]. These were all identified in patients who had traveled to India or Pakistan, the majority of whom received medical care there. </p><p>Isolates of <em>P. aeruginosa</em> which co-harbor genes for both KPC and NDM have also been described [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/70\" class=\"abstract_t\">70</a>].</p><p class=\"headingAnchor\" id=\"H561110\"><span class=\"h3\">Class D carbapenemases</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While A. baumannii carrying OXA-23-, <span class=\"nowrap\">OXA-24/40-,</span> and OXA-58-type carbapenemases are especially problematic in Europe, they have also been recovered from medical centers in Eastern Asia, the Middle East, Australia, South America, and the United States [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/36\" class=\"abstract_t\">36</a>]. The first isolate of <em>K. pneumoniae </em>with OXA-48 was identified in Turkey; since then, hospital outbreaks from that country have been reported [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/71\" class=\"abstract_t\">71</a>]. Enterobacteriaceae with OXA-48-type enzymes have subsequently been recovered in the United States, Europe, the Middle East, and Northern Africa.</p><p class=\"headingAnchor\" id=\"H21045526\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenemase-producing organisms can arise from previously carbapenemase-negative strains by acquisition of genes from other bacteria. Use of broad spectrum cephalosporins <span class=\"nowrap\">and/or</span> carbapenems is an important risk factor for the development of colonization or infection with such pathogens [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/30,64,72\" class=\"abstract_t\">30,64,72</a>]. As an example, in one case-control study, 86 percent of patients with a KPC-producing Enterobacteriaceae isolate (n = 91) had a history of cephalosporin use in the past three months, compared with 69 percent of those with extended-spectrum beta-lactamase-producing isolates and 27 percent of those with fully susceptible isolates [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/73\" class=\"abstract_t\">73</a>]. </p><p>Although a risk factor, prior receipt of carbapenems is not essential for acquisition of these strains. Reported carbapenem use among patients prior to the isolation of MBL, for example, varies from 15 to 75 percent [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/55,56\" class=\"abstract_t\">55,56</a>]. </p><p>Additional risk factors that have been associated with infection or colonization with a carbapenemase-producing organism include the following [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/16,18,24,56,58,74-77\" class=\"abstract_t\">16,18,24,56,58,74-77</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Trauma </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diabetes </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignancy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organ transplantation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mechanical ventilation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indwelling urinary or venous catheters</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overall poor functional status or severe illness</p><p/><p>Clinicians should be also aware of the possibility of NDM-1-producing Enterobacteriaceae in patients who have received medical care in India and Pakistan [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"#H92008117\" class=\"local\">'Metallo-beta-lactamases'</a> above.) </p><p class=\"headingAnchor\" id=\"H21045553\"><span class=\"h2\">Transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many carbapenemases reside on mobile genetic elements, such as transposons or plasmids, and have the potential for widespread transmission to other isolates and genera of bacteria. Furthermore, Enterobacteriaceae, which may harbor carbapenemase-encoding genes, can spread from person to person.</p><p>One particular clone of <em>K. pneumoniae </em>that carries the KPC gene has been reported as the predominant isolate across several geographic areas, suggesting cross-infection within and outside of health care systems [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/71\" class=\"abstract_t\">71</a>]. </p><p>Limited data using DNA fingerprinting and pulse-field gel electrophoresis also suggest cross-transmission of bacteria with MBLs within hospitals [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/29\" class=\"abstract_t\">29</a>]. This was illustrated in a study of 66 MBL-positive isolates from 54 hospitalized patients in a hospital outbreak [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/60\" class=\"abstract_t\">60</a>]. Environmental screening isolated MBL-producing organisms from sinks and stethoscopes, suggesting these as possible environmental reservoirs; interestingly, there were no positive cultures from the hands of the 10 health care workers screened. The outbreak was curtailed following intensive environmental cleaning with hypochlorite, replacement of poorly designed sinks, and disassembling and cleaning of stethoscopes. Another outbreak of NDM-producing <em>E. coli</em> implicated contaminated endoscopes [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/78\" class=\"abstract_t\">78</a>]. (See <a href=\"topic.htm?path=endoscope-disinfection#H1562522656\" class=\"medical medical_review\">&quot;Endoscope disinfection&quot;, section on 'Carbapenem-resistant Enterobacteriaceae'</a>.)</p><p>NDM-1-positive bacteria have been identified in public water supplies in India, highlighting the potential for environmental dissemination, and the importance of environmental surveillance [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/79\" class=\"abstract_t\">79</a>]. In addition, two isolates of <em>Pseudomonas aeruginosa</em> containing an MBL gene (<em>bla</em> VIM) have been also detected from aquatic sources (one isolate from a river and the second from sewage), raising the possibility of aquatic reservoirs for these organisms [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/80\" class=\"abstract_t\">80</a>]. </p><p>Patients themselves may also serve as an important reservoir for resistant Enterobacteriaceae, as intestinal colonization with carbapenemase-producing organisms has been reported [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,29,81,82\" class=\"abstract_t\">22,29,81,82</a>]. </p><p class=\"headingAnchor\" id=\"H92009070\"><span class=\"h1\">DETECTION</span></p><p class=\"headingAnchor\" id=\"H92009113\"><span class=\"h2\">Clinical laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most <em>K. pneumoniae </em>and <em>E. coli</em> without carbapenemases have minimum inhibitory concentrations (MICs) to <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> and <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> that are &le;0.5 <span class=\"nowrap\">mcg/mL</span>. Thus, the identification of <em>E. coli</em> or <em>K. pneumoniae </em>with overt resistance to any of the carbapenems should raise suspicion that it may be harboring a carbapenemase enzyme. Certain susceptibility patterns in other Enterobacteriaceae may be suggestive of the presence of a carbapenemase. As an example, recovery of an isolate that is susceptible to third generation cephalosporins but resistant to imipenem should raise the possibility of an underlying <em>Serratia marcescens</em> enzyme (SMC) in <em>Serratia</em> species and a non-metalloenzyme carbapenemase (NMC) or imipenem-hydrolyzing beta-lactamase (IMI) in <em>Enterobacter</em> species [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/6-8\" class=\"abstract_t\">6-8</a>]. </p><p>Detection of carbapenemase-producing Enterobacteriaceae can be problematic. Some isolates have MICs that fall just below the traditional breakpoints for susceptibility and therefore may not be recognized as carbapenemase producers by the clinical laboratory [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24,60,83-86\" class=\"abstract_t\">24,60,83-86</a>]. In one report, up to 87 percent of <em>K. pneumoniae </em>carbapenemase (KPC)-producing <em>K. pneumoniae </em>were reported to be susceptible to carbapenems according to breakpoints typically in use prior to 2011 [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/87\" class=\"abstract_t\">87</a>]. Detection of Enterobacteriaceae harboring OXA-48-type enzymes can be similarly challenging [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/46\" class=\"abstract_t\">46</a>]. </p><p>In 2010, the Clinical and Laboratory Standards Institute (CLSI) updated <a href=\"http://www.cdc.gov/hai/organisms/cre/cre-toolkit/rCREprevention-AppendixA.html&amp;token=DmaQh4zjn8TGn+CNksd6KoOt7omZGSCY7O5LyYIoX983lGnoyxp+GVmxlxlplbeyJM74Tis91U22Jvb/v6NseoMi8qvlbKxlOmIRfBRScKA=&amp;TOPIC_ID=471\" target=\"_blank\" class=\"external\">new MIC and disk diffusion breakpoints</a> for the Enterobacteriaceae based on pharmacokinetic-pharmacodynamic data of recommended dosage regimens [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/88-91\" class=\"abstract_t\">88-91</a>]. The new MIC breakpoints are one to three doubling dilutions lower than the original breakpoints, and the new disk diffusion criteria include larger zone diameters than those in previous guidelines. Thus, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant. In clinical laboratories that have implemented these new breakpoints, additional tests to detect extended-spectrum beta-lactamases and carbapenemases need not be routinely performed for clinical management. However, phenotypic or genotypic testing for carbapenemases may be useful for isolates that test in the susceptible range to carbapenems but have reduced susceptibility. Additionally, carbapenemase testing may be performed for infection control purposes, and isolates may be forwarded through state public health laboratories to the United States Centers for Disease Control and Prevention (CDC) for further characterization [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"#H92009120\" class=\"local\">'Other phenotypic tests'</a> below.) </p><p><em>P. aeruginosa</em> and <em>A. baumannii</em> can become resistant to carbapenems without acquiring a carbapenemase; determining which isolates have an acquired carbapenemase based on susceptibility profiles can be difficult. In regions where metallo-beta-lactamases (MBL) and OXA enzymes are endemic, isolates of <em>P. aeruginosa</em> and <em>A. baumannii</em> that are highly resistant to carbapenems, cephalosporins, and penicillins should be suspected of carrying one of these enzymes. In addition, presence of an underlying MBL should be considered if an isolate retains susceptibility to <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H92009120\"><span class=\"h2\">Other phenotypic tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For laboratories that have implemented the updated 2010 CLSI breakpoints for carbapenem susceptibility (see <a href=\"#H92009113\" class=\"local\">'Clinical laboratory testing'</a> above), additional tests are no longer routinely recommended for detection of carbapenemase-producing organisms. For clinical laboratories that have not yet implemented the updated CLSI breakpoints, additional tests are often employed to improve the detection of carbapenemases. </p><p>For example, the modified Hodge test can be used to detect carbapenemase activity [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/93,94\" class=\"abstract_t\">93,94</a>]. This test involves streaking a clinical isolate near an <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> disk that has been placed on an agar plate containing a susceptible control organism. Growth of the control organism around the imipenem disk in the region of the streak suggests carbapenemase activity in the clinical isolate. However, the modified Hodge test has several drawbacks. Assessment of the test result may be difficult and subject to individual interpretation. Additionally, it has poor sensitivity for metallo-beta-lactamase (MBL) detection, although this can be improved with the addition of zinc [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/95\" class=\"abstract_t\">95</a>]. False positive Hodge tests have also been reported [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/96\" class=\"abstract_t\">96</a>]. </p><p>Various phenotypic tests can be used to suggest the presence of particular carbapenemases in organisms. Inoculation on chromogenic agar can be used to screen surveillance cultures for carbapenemase-producing pathogens [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/97\" class=\"abstract_t\">97</a>]. Using the inhibitory property of EDTA (an ion chelator) against metallo-beta-lactamases, several phenotypic tests have been developed to screen isolates for these enzymes [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,28,98-100\" class=\"abstract_t\">22,28,98-100</a>]. These tests include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The double-disc synergy test using carbapenem and EDTA discs</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Carbapenem discs with and without EDTA</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The commercially available MBL Etest [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/99-104\" class=\"abstract_t\">99-104</a>] </p><p/><p>Commercially available rapid molecular tests can reliably document the presence of KPC [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/105,106\" class=\"abstract_t\">105,106</a>] and metallo-beta-lactamases [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/106\" class=\"abstract_t\">106</a>] in positive blood culture samples. (See <a href=\"#H92009127\" class=\"local\">'Direct genotypic identification'</a> below.)</p><p class=\"headingAnchor\" id=\"H92009127\"><span class=\"h2\">Direct genotypic identification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Identification of specific carbapenemases can be accomplished utilizing molecular techniques [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24,39,85,107-109\" class=\"abstract_t\">24,39,85,107-109</a>]. These include multiplex polymerase chain reaction (PCR) assays and DNA microarrays that can screen at once for several different types of enzymes, including <em>K. pneumoniae</em> carbapenemases, specific MBLs, and OXA-type carbapenemases. Detection of organisms harboring these enzymes will be greatly improved as these technologies become incorporated into clinical practice. They are generally used for infection control purposes. (See <a href=\"#H12\" class=\"local\">'Infection control'</a> below.) </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CLINICAL DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenemase-producing organisms can cause clinical infections or asymptomatic colonization [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/18,55\" class=\"abstract_t\">18,55</a>]. Bloodstream infections, ventilator-associated pneumonia, urinary tract infection, and central venous catheter infections have been described [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24,29,60,103\" class=\"abstract_t\">24,29,60,103</a>]. These organisms have been isolated from respiratory tract specimens, abdominal swabs, catheters, abscesses, urine, and surgical wounds [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/29,30,55,60,103,110,111\" class=\"abstract_t\">29,30,55,60,103,110,111</a>]. Sporadic hospital-acquired infections and outbreaks due to hospital-based clonal spread have been described in both tertiary and community hospitals [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24,30,60,112\" class=\"abstract_t\">24,30,60,112</a>].</p><p>Serious infections with carbapenemase-producing bacteria have a relatively poor prognosis [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/113-115\" class=\"abstract_t\">113-115</a>]. Compared with patients who have bacteremia due to carbapenem-resistant (but not carbapenemase-producing) Enterobacteriaceae, patients with bacteremia due to carbapenemase-producing pathogens have a three-fold higher mortality [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/113\" class=\"abstract_t\">113</a>].</p><p>The specific clinical syndromes are discussed in more detail in the corresponding topic reviews.</p><p class=\"headingAnchor\" id=\"H17256132\"><span class=\"h1\">SUSCEPTIBILITY TESTING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to resistance to the penicillins, cephalosporins, and carbapenems, resistance genes for other antibiotics, including aminoglycosides and fluoroquinolones, are frequently present in carbapenemase-producing strains [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,29\" class=\"abstract_t\">22,29</a>]. For KPC-carrying <em>K. pneumoniae</em>, resistance rates of 98 percent have been reported for the fluoroquinolones, and approximately 50 percent are resistant to <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> and <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/116\" class=\"abstract_t\">116</a>]. Current beta-lactamase inhibitors are ineffective against metallo-beta-lactamases (MBL) and many OXA-type beta-lactamases.</p><p>Additional antibiotic susceptibility testing should be requested for aminoglycosides (particularly <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>), <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> or <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">polymyxin B</a>, <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a> (particularly for urinary tract isolates), <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/117,118\" class=\"abstract_t\">117,118</a>], and <a href=\"topic.htm?path=ceftolozane-and-tazobactam-drug-information\" class=\"drug drug_general\">ceftolozane-tazobactam</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/119\" class=\"abstract_t\">119</a>]. Based on in vitro data, ceftazidime-avibactam may be active against KPC- and some OXA-type carbapenemase producing organisms, but not MBL-producers [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/120\" class=\"abstract_t\">120</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal treatment of infection due to carbapenemase-producing organisms is uncertain, and antibiotic options are limited. Management of patients with infections due to carbapenemase-producing organisms should be done in consultation with an expert in the treatment of multidrug resistant bacteria. </p><p>In outbreak settings, empiric therapy against carbapenemase-producing bacteria should be considered for patients with serious infections until culture and susceptibility data become available.</p><p class=\"headingAnchor\" id=\"H1136483527\"><span class=\"h2\">Therapy for carbapenemase-producing Enterobacteriaceae</span></p><p class=\"headingAnchor\" id=\"H1155732076\"><span class=\"h3\">Serious infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Therapeutic options for carbapenemase-producing Enterobacteriaceae are limited, and no one antibiotic regimen has been clearly defined to be superior over another. For most serious infections, the choice of therapy depends on the type of carbapenemase present and the susceptibility profile of the isolate:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For infections caused by <em>Klebsiella pneumoniae</em> carbapenemase (KPC)-producing organisms, we favor <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> if the organism is susceptible. If the isolate has an elevated minimum inhibitory concentration (MIC) to ceftazidime-avibactam (but remains within the susceptible range), we add a second agent, typically a carbapenem. <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">Meropenem-vaborbactam</a> is another agent that can be used for KPC-producing organisms, although clinical experience with this is even more limited than with ceftazidime-avibactam. When beta-lactam agents are used for carbapenemase-producing isolates, prolonged infusion dosing can be considered. (See <a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Prolonged infusions of beta-lactam antibiotics&quot;</a>.)</p><p/><p class=\"bulletIndent1\">If neither <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> nor <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">meropenem-vaborbactam</a> is used, a polymyxin-based combination regimen, as detailed below, is appropriate as long as the isolate is susceptible. </p><p/><p class=\"bulletIndent1\">These newer beta-lactam-beta-lactamase combinations had a better safety profile, more reliable dosing, and greater susceptibility rates compared with polymyxins. Efficacy data supporting their use are limited but promising [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/121-125\" class=\"abstract_t\">121-125</a>]. As an example, in one retrospective study of patients with KPC-producing Enterobacteriaceae, treatment with <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> was associated with a lower adjusted 30-day mortality rate compared with <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/121\" class=\"abstract_t\">121</a>]. However, these observational studies are subject to selection bias, and randomized controlled trials are warranted to confirm the observation. Moreover, emergence of resistance to ceftazidime-avibactam during therapy has been reported [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/126\" class=\"abstract_t\">126</a>]. In vitro and in vivo evidence suggests adding a second agent (typically a carbapenem) may be synergistic [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/127,128\" class=\"abstract_t\">127,128</a>]. <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">Meropenem-vaborbactam</a> also demonstrated in vitro and in vivo efficacy against KPC-producing isolates [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/129,130\" class=\"abstract_t\">129,130</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For infections caused by isolates producing metallo-beta-lactamases (MBL), we suggest a polymyxin-based combination regimen, as detailed below, if the isolate is susceptible. For strains that are highly resistant (including to polymyxins), the combination of <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> plus <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> may be a possible option. When beta-lactam agents are used for carbapenemase-producing isolates, prolonged infusion dosing can be considered. (See <a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Prolonged infusions of beta-lactam antibiotics&quot;</a>.)</p><p/><p class=\"bulletIndent1\">MBLs confer resistance to all beta-lactam-type antibiotics except <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/118\" class=\"abstract_t\">118</a>], but MBL-producing isolates often produce other extended-spectrum beta-lactamases that confer resistance to aztreonam. Although MBLs are not inhibited by any of the available beta-lactamase inhibitors, combining <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> and aztreonam can have a synergistic effect, as the avibactam can inactivate the other beta-lactamases to render the aztreonam active. This combination has been used to successfully treat a small number of patients with extremely resistant MBL-producing pathogens [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/131-133\" class=\"abstract_t\">131-133</a>]. </p><p/><p>When a polymyxin (<a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> or <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">polymyxin B</a>) is used for either KPC- or metallo-beta-lactamase-producing Enterobacteriaceae, we typically use it with a second active agent [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/116,134\" class=\"abstract_t\">116,134</a>]. A potential second agent is <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a>, especially if the isolate has an MIC to meropenem &le;8 <span class=\"nowrap\">mcg/mL</span>. <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">Tigecycline</a> could also be considered as a second agent, especially for infections involving the gastrointestinal tract and lungs, given its penetration into these tissues. Optimizing the dosing of polymyxins is discussed elsewhere. (See <a href=\"topic.htm?path=polymyxins-an-overview#H7\" class=\"medical medical_review\">&quot;Polymyxins: An overview&quot;, section on 'Intravenous administration'</a>.)</p><p>The rationale for using two or more agents includes the high mortality associated with serious CRE infections, evidence suggesting that combination therapy is associated with reduced mortality, the concern for emergence of resistance during monotherapy, and the lack of clearly effective single-drug alternatives. Several observational studies have suggested that treatment with combination therapy may improve mortality [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/120,135-141\" class=\"abstract_t\">120,135-141</a>]. As an example, in a retrospective study of 661 patients with an infection due to <em>K. pneumoniae</em> confirmed by polymerase chain reaction to harbor the KPC gene, definitive therapy with combination therapy was associated with a lower 14-days mortality compared with therapy with a single-active agent (30.2 versus 38.4 percent) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/142\" class=\"abstract_t\">142</a>]. This difference was particularly evident among the 447 patients with bacteremia, who had mortality rates of 32 versus 51.3 percent with combination therapy versus monotherapy, respectively. Most combination regimens included a carbapenem; when the isolate had a <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> MIC &ge;16 <span class=\"nowrap\">mg/L,</span> mortality rates among those who received a combination regimen with meropenem and those who received monotherapy were not statistically different [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/138\" class=\"abstract_t\">138</a>]. An earlier analysis of a smaller subset of these patients reported that patients treated with a combination of a polymyxin plus <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> had a mortality rate of 30 percent (7 of 23), while the regimen of <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a>, tigecycline, and extended-infusion meropenem (a dose of 2 grams infused over three or more hours every eight hours) was associated with the lowest mortality rate (2 of 16 [12.5 percent]) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/10,138\" class=\"abstract_t\">10,138</a>]. A systematic review of 20 observational studies also concluded that combination therapy may offer a survival advantage in severely ill patients [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/140\" class=\"abstract_t\">140</a>]. </p><p>Unfortunately, resistance to polymyxins is an increasing problem [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/143-149\" class=\"abstract_t\">143-149</a>]. Development of polymyxin resistance in <em>K. pneumoniae </em>during polymyxin therapy has been documented [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/145\" class=\"abstract_t\">145</a>], and the spread of isolates possessing the <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> resistance gene <em>mcr-1</em> will likely further limit the utility of polymyxins [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/150\" class=\"abstract_t\">150</a>]. Infection with a polymyxin-resistant strain has been found to be an independent risk factor for mortality [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/146,148\" class=\"abstract_t\">146,148</a>]. (See <a href=\"topic.htm?path=polymyxins-an-overview#H3\" class=\"medical medical_review\">&quot;Polymyxins: An overview&quot;, section on 'Resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H140542872\"><span class=\"h3\">Uncomplicated cystitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolates causing uncomplicated urinary tract infections can often be successfully treated with a single active agent, such as an aminoglycoside [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/117\" class=\"abstract_t\">117</a>] or <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a>. Aminoglycosides can be given as a consolidated, extended-interval dose for 7 to 14 days, depending on response to therapy (see <a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">&quot;Dosing and administration of parenteral aminoglycosides&quot;</a>). Fosfomycin can be given intravenously or as a single 3 g oral dose. Of note, intravenous fosfomycin is not available in many countries, including the United States and Australia.</p><p>Use of a single active agent in uncomplicated urinary tract infections is supported by several small studies [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/151-153\" class=\"abstract_t\">151-153</a>]. In one study of a panel of 81 carbapenem-resistant Enterobacteriaceae of various types and species, 60 percent tested susceptible to <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/151\" class=\"abstract_t\">151</a>]. In a small prospective study of 11 patients, an intravenous preparation of fosfomycin was used to successfully treat various carbapenem-resistant <em>K. pneumoniae </em>infections [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/153\" class=\"abstract_t\">153</a>]. </p><p class=\"headingAnchor\" id=\"H1136483707\"><span class=\"h2\">Therapy for carbapenem-resistant A. baumannii and P. aeruginosa</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenem-resistant <em>A. baumannii </em>and <em>P. aeruginosa</em> are typically resistant to all beta-lactams and fluoroquinolones. The intrinsic resistance of these organisms further limits antibiotic options. Although sulbactam has been used to treat some infections due to <em>A. baumannii</em>, most multidrug-resistant isolates of <em>A. baumannii</em> have reduced susceptibility to this agent [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/40,116,154,155\" class=\"abstract_t\">40,116,154,155</a>]. In vitro activity of <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> is similar to <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> alone for most <em>A. baumannii</em> and many <em>P. aeruginosa</em> [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/156\" class=\"abstract_t\">156</a>]. Aminoglycosides may be useful, particularly for urinary tract infections, assuming susceptibility is retained for one of these antibiotics. <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">Aztreonam</a> may also be considered for MBL-possessing <em>P. aeruginosa</em>, but supporting clinical data is lacking. <em>P. aeruginosa</em> are intrinsically resistant to <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, the emergence of tigecycline-resistant <em>A. baumannii</em> has been reported [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/157\" class=\"abstract_t\">157</a>]. Most multidrug-resistant <em>A. baumannii</em> and <em>P. aeruginosa</em> retain susceptibility for the polymyxins. Therefore, the polymyxins (ie, <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> and <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">polymyxin B</a>) are usually the cornerstones for therapy. Combination therapy is also advised when polymyxins are used to treat multidrug-resistant <em>A. baumannii</em> and <em>P. aeruginosa</em>. </p><p>Detailed discussion of the management of multi-drug resistant <em>A. baumannii</em> and <em>P. aeruginosa</em> are found in detail elsewhere. (See <a href=\"topic.htm?path=acinetobacter-infection-treatment-and-prevention#H688213168\" class=\"medical medical_review\">&quot;Acinetobacter infection: Treatment and prevention&quot;, section on 'Resistant isolates'</a> and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675731\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Strategies for multidrug-resistant organisms'</a>.)</p><p>For ventilator-associated pneumonia due to these organisms, adjunctive use of aerosolized <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> has been evaluated. This is also discussed in detail elsewhere. (See <a href=\"topic.htm?path=polymyxins-an-overview#H8\" class=\"medical medical_review\">&quot;Polymyxins: An overview&quot;, section on 'Inhaled administration'</a> and <a href=\"topic.htm?path=acinetobacter-infection-treatment-and-prevention#H1211132\" class=\"medical medical_review\">&quot;Acinetobacter infection: Treatment and prevention&quot;, section on 'Pneumonia'</a> and <a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia#H1210512861\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa pneumonia&quot;, section on 'Inhaled antibiotics'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">INFECTION CONTROL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hospitalized patients infected or colonized with carbapenemase-producing bacteria should be placed on contact precautions [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/29,58,60,81,158\" class=\"abstract_t\">29,58,60,81,158</a>]. Guidelines from the Society of Healthcare Epidemiology of America recommend that inpatient contact precautions be continued for the duration of inpatient hospitalization [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/159\" class=\"abstract_t\">159</a>]. Contact precautions should also be maintained indefinitely (ie, during future hospitalizations) given the prolonged colonization with such organisms and the limited treatment options. Other standard measures, such as hand hygiene, minimizing the use of invasive devices, and antimicrobial stewardship, are important to infection control in general and likely to limit spread of resistant organisms. </p><p>Screening high-risk patients to detect rectal colonization has been suggested as an important infection control modality [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22,29,81,82\" class=\"abstract_t\">22,29,81,82</a>]. Several studies have documented reduced transmission of KPC-producing <em>K. pneumoniae </em>when comprehensive infection control protocols, including active surveillance, have been enacted [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/160-163\" class=\"abstract_t\">160-163</a>]. Although the impact of surveillance itself is difficult to assess, it may be useful in the setting of outbreaks due to carbapenem-resistant organisms, as recommended by the United States <a href=\"http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf&amp;token=mjmpv7xMHRIW2nr+3NCnsXr4/4aq7rC/62WvWg0JZtS8NKMbE4fSolvuRPBQQoGBy1K948twkSAM4JYKShDyuQ==&amp;TOPIC_ID=471\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention</a> (CDC), or among patients with recent travel to areas where carbapenemases are more prevalent. Molecular tests that detect genes associated with carbapenem resistance can aid in detection of rectal colonization. Examples include the Xpert Carba-R assay (detects genes for KPC, NDM, VIM, IMP, and OXA-48) and the BD-MAX (detects genes for KPC, NDM, VIM, and OXA-48) [<a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/164,165\" class=\"abstract_t\">164,165</a>]. Availability of these assays varies by country. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The carbapenem-hydrolyzing beta-lactamase is an important emerging mechanism of antimicrobial resistance among nosocomial gram-negative pathogens. These enzymes are classified on the basis of their amino acid homology; Classes A, B, and D are of greatest clinical importance. (See <a href=\"#H2\" class=\"local\">'Classification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinically most important of the Class A carbapenemases is the <em>Klebsiella pneumoniae</em> carbapenemase (KPC) group, which has been implicated in several outbreaks. (See <a href=\"#H3\" class=\"local\">'Class A beta-lactamases'</a> above and <a href=\"#H19876835\" class=\"local\">'Klebsiella pneumoniae carbapenemase (KPC)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Class B beta-lactamases are known as the metallo-beta-lactamases (MBLs), which are named for their dependence upon zinc for efficient hydrolysis of beta-lactams. The New Delhi metallo-beta-lactamase (NDM-1) is an important emerging carbapenemase in this group. (See <a href=\"#H4\" class=\"local\">'Class B beta-lactamases'</a> above and <a href=\"#H19877222\" class=\"local\">'New Delhi metallo-beta-lactamase (NDM-1)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Class D beta-lactamases are referred to as OXA-type enzymes because of their preferential ability to hydrolyze <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> (rather than penicillin). (See <a href=\"#H5\" class=\"local\">'Class D beta-lactamases'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Implementation of the lower <a href=\"http://www.cdc.gov/hai/organisms/cre/cre-toolkit/rCREprevention-AppendixA.html&amp;token=DmaQh4zjn8TGn+CNksd6KoOt7omZGSCY7O5LyYIoX983lGnoyxp+GVmxlxlplbeyJM74Tis91U22Jvb/v6NseoMi8qvlbKxlOmIRfBRScKA=&amp;TOPIC_ID=471\" target=\"_blank\" class=\"external\">2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints</a> for carbapenem susceptibility improves the detection of carbapenemase-producing Enterobacteriaceae. Identifying strains <em>of P. aeruginosa</em> or <em>A. baumannii</em> with carbapenemases can be difficult. Isolates resistant to penicillins, cephalosporins, and carbapenems with retained susceptibility to <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> should be suspected of carrying an MBL. (See <a href=\"#H92009070\" class=\"local\">'Detection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of broad spectrum cephalosporins <span class=\"nowrap\">and/or</span> carbapenems is an important risk factor for the development of colonization or infection with carbapenemase-producing organisms, although prior receipt of carbapenems is not essential for acquisition of these strains. (See <a href=\"#H21045526\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Carbapenemase-producing organisms can cause clinical infections or asymptomatic colonization. Carbapenemase-producing bacteria have been implicated in a variety of infections, including bacteremia, ventilator-associated pneumonia, urinary tract infection, and central venous catheter infection. (See <a href=\"#H7\" class=\"local\">'Clinical disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Selection of antibiotic therapy should be tailored according to the antimicrobial susceptibility test result. In particular, additional antibiotic susceptibility testing should be requested for <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a>, <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">meropenem-vaborbactam</a>, <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a>, <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, and <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a>. (See <a href=\"#H17256132\" class=\"local\">'Susceptibility testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with serious infections due to carbapenemase-producing Enterobacteriaceae, antibiotic selection depends on the type of carbapenemase and the susceptibility profile of the isolate (see <a href=\"#H1155732076\" class=\"local\">'Serious infections'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For <em>Klebsiella pneumoniae</em> carbapenemases (KPC), we suggest <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">ceftazidime-avibactam</a> if the organism is susceptible (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">Meropenem-vaborbactam</a> is another option. If neither of these can be used, a polymyxin-based regimen is the alternative.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For metallo-beta-lactamases, we suggest a polymyxin-based regimen if the isolate is susceptible (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When a polymyxin (<a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> or <a href=\"topic.htm?path=polymyxin-b-drug-information\" class=\"drug drug_general\">polymyxin B</a>) is used, we suggest using a second active agent in combination with the polymyxin (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Potential second agents include <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> or, for infections involving the gastrointestinal tract or lungs, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with uncomplicated urinary tract infections caused by carbapenemase-producing Enterobacteriaceae can often be successfully treated with a single active agent (eg, an aminoglycoside or <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a>). (See <a href=\"#H140542872\" class=\"local\">'Uncomplicated cystitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymyxins are the cornerstones of therapy for carbapenem-resistant <em>A. baumannii</em> and <em>P. aeruginosa</em> and are generally used in combination with another agent. (See <a href=\"#H1136483707\" class=\"local\">'Therapy for carbapenem-resistant A. baumannii and P. aeruginosa'</a> above and <a href=\"topic.htm?path=acinetobacter-infection-treatment-and-prevention#H688213168\" class=\"medical medical_review\">&quot;Acinetobacter infection: Treatment and prevention&quot;, section on 'Resistant isolates'</a> and <a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia#H1410951\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa pneumonia&quot;, section on 'Strategies for drug resistant isolates'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hospitalized patients infected or colonized with carbapenemase-producing bacteria should be placed on contact precautions for the duration of their hospitalization. Screening high-risk patients to detect rectal colonization may also be helpful in controlling transmission. (See <a href=\"#H12\" class=\"local\">'Infection control'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/1\" class=\"nounderline abstract_t\">Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/2\" class=\"nounderline abstract_t\">Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/3\" class=\"nounderline abstract_t\">Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/4\" class=\"nounderline abstract_t\">Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41:5407.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/5\" class=\"nounderline abstract_t\">Walther-Rasmussen J, H&oslash;iby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60:470.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/6\" class=\"nounderline abstract_t\">Queenan AM, Shang W, Schreckenberger P, et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 2006; 50:3485.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/7\" class=\"nounderline abstract_t\">Rasmussen BA, Bush K, Keeney D, et al. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother 1996; 40:2080.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/8\" class=\"nounderline abstract_t\">Pottumarthy S, Moland ES, Juretschko S, et al. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg Infect Dis 2003; 9:999.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/9\" class=\"nounderline abstract_t\">Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/10\" class=\"nounderline abstract_t\">Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002; 49:561.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/11\" class=\"nounderline abstract_t\">Jeong SH, Bae IK, Kim D, et al. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea. Antimicrob Agents Chemother 2005; 49:4809.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/12\" class=\"nounderline abstract_t\">Wolter DJ, Kurpiel PM, Woodford N, et al. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 2009; 53:557.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/13\" class=\"nounderline abstract_t\">Hidalgo-Grass C, Warburg G, Temper V, et al. KPC-9, a novel carbapenemase from clinical specimens in Israel. Antimicrob Agents Chemother 2012; 56:6057.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/14\" class=\"nounderline abstract_t\">Navon-Venezia S, Chmelnitsky I, Leavitt A, et al. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/15\" class=\"nounderline abstract_t\">Villegas MV, Lolans K, Correa A, et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51:1553.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/16\" class=\"nounderline abstract_t\">Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/17\" class=\"nounderline abstract_t\">Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/18\" class=\"nounderline abstract_t\">Hossain A, Ferraro MJ, Pino RM, et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 2004; 48:4438.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/19\" class=\"nounderline abstract_t\">Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/20\" class=\"nounderline abstract_t\">Martins WM, Nicoletti AG, Santos SR, et al. Frequency of BKC-1-Producing Klebsiella Species Isolates. Antimicrob Agents Chemother 2016; 60:5044.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/21\" class=\"nounderline abstract_t\">Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/22\" class=\"nounderline abstract_t\">Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/23\" class=\"nounderline abstract_t\">Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/24\" class=\"nounderline abstract_t\">Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41:1549.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/25\" class=\"nounderline abstract_t\">Houang ET, Chu YW, Lo WS, et al. Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother 2003; 47:1382.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/26\" class=\"nounderline abstract_t\">Hawkey PM, Xiong J, Ye H, et al. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194:53.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/27\" class=\"nounderline abstract_t\">Shiroto K, Ishii Y, Kimura S, et al. Metallo-beta-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan. J Med Microbiol 2005; 54:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/28\" class=\"nounderline abstract_t\">Rossolini GM. Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis 2005; 41:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/29\" class=\"nounderline abstract_t\">Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42:2006.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/30\" class=\"nounderline abstract_t\">Herbert S, Halvorsen DS, Leong T, et al. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007; 28:98.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/31\" class=\"nounderline abstract_t\">Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/32\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:750.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/33\" class=\"nounderline abstract_t\">Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011; 66:689.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/34\" class=\"nounderline abstract_t\">Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/35\" class=\"nounderline abstract_t\">Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67:1569.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/36\" class=\"nounderline abstract_t\">Walther-Rasmussen J, H&oslash;iby N. OXA-type carbapenemases. J Antimicrob Chemother 2006; 57:373.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/37\" class=\"nounderline abstract_t\">Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41:3403.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/38\" class=\"nounderline abstract_t\">Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea. J Clin Microbiol 2005; 43:2241.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/39\" class=\"nounderline abstract_t\">Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258:72.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/40\" class=\"nounderline abstract_t\">Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/41\" class=\"nounderline abstract_t\">Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/42\" class=\"nounderline abstract_t\">Bou G, Oliver A, Mart&iacute;nez-Beltr&aacute;n J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/43\" class=\"nounderline abstract_t\">Lopez-Otsoa F, Gallego L, Towner KJ, et al. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol 2002; 40:4741.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/44\" class=\"nounderline abstract_t\">H&eacute;ritier C, Dubouix A, Poirel L, et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55:115.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/45\" class=\"nounderline abstract_t\">Vahaboglu H, Budak F, Kasap M, et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/46\" class=\"nounderline abstract_t\">Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/47\" class=\"nounderline abstract_t\">Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Healthcare-associated infections; Tracking CRE. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html (Accessed on October 16, 2015).</li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/49\" class=\"nounderline abstract_t\">Guh AY, Bulens SN, Mu Y, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA 2015; 314:1479.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/50\" class=\"nounderline abstract_t\">Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012; 4:148ra116.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/51\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013; 62:165.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/52\" class=\"nounderline abstract_t\">Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol 2013; 34:144.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/53\" class=\"nounderline abstract_t\">Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/54\" class=\"nounderline abstract_t\">Hoenigl M, Valentin T, Zarfel G, et al. Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria. Antimicrob Agents Chemother 2012; 56:2158.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/55\" class=\"nounderline abstract_t\">Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/56\" class=\"nounderline abstract_t\">Wei ZQ, Du XX, Yu YS, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007; 51:763.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/57\" class=\"nounderline abstract_t\">Chang LW, Buising KL, Jeremiah CJ, et al. Managing a nosocomial outbreak of carbapenem-resistant Klebsiella pneumoniae: an early Australian hospital experience. Intern Med J 2015; 45:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/58\" class=\"nounderline abstract_t\">Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50:2880.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/59\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Update: detection of a verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae --- United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/60\" class=\"nounderline abstract_t\">Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/61\" class=\"nounderline abstract_t\">Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004; 54:699.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/62\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Klebsiella pneumoniae associated with a long-term--care facility --- West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep 2011; 60:1418.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/63\" class=\"nounderline abstract_t\">G&ouml;ttig S, Hamprecht AG, Christ S, et al. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-&beta;-lactamase with increased carbapenemase activity. J Antimicrob Chemother 2013; 68:1737.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/64\" class=\"nounderline abstract_t\">Nou&eacute;r SA, Nucci M, de-Oliveira MP, et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005; 49:3663.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/65\" class=\"nounderline abstract_t\">Peleg AY, Bell JM, Hofmeyr A, Wiese P. Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes. J Antimicrob Chemother 2006; 57:794.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/66\" class=\"nounderline abstract_t\">Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-&beta;-lactamase. Clin Infect Dis 2011; 52:481.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/67\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep 2012; 61:446.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/68\" class=\"nounderline abstract_t\">Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/69\" class=\"nounderline abstract_t\">Thoms-Rodriguez CA, Mazzulli T, Christian N, et al. New Delhi metallo-&beta;-lactamase in Jamaica. J Infect Dev Ctries 2016; 10:183.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/70\" class=\"nounderline abstract_t\">Paul D, Dhar Chanda D, Maurya AP, et al. Co-Carriage of blaKPC-2 and blaNDM-1 in Clinical Isolates of Pseudomonas aeruginosa Associated with Hospital Infections from India. PLoS One 2015; 10:e0145823.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/71\" class=\"nounderline abstract_t\">Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/72\" class=\"nounderline abstract_t\">Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/73\" class=\"nounderline abstract_t\">Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/74\" class=\"nounderline abstract_t\">Deshpande P, Shetty A, Kapadia F, et al. New Delhi metallo 1: have carbapenems met their doom? Clin Infect Dis 2010; 51:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/75\" class=\"nounderline abstract_t\">Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/76\" class=\"nounderline abstract_t\">Toleman MA, Biedenbach D, Bennett DM, et al. Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J Antimicrob Chemother 2005; 55:61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/77\" class=\"nounderline abstract_t\">Borgmann S, Wolz C, Gr&ouml;bner S, et al. Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area. J Hosp Infect 2004; 57:308.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/78\" class=\"nounderline abstract_t\">Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-&beta;-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 2014; 312:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/79\" class=\"nounderline abstract_t\">Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/80\" class=\"nounderline abstract_t\">Quinteira S, Peixe L. Multiniche screening reveals the clinically relevant metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa far from the hospital setting: an ongoing dispersion process? Appl Environ Microbiol 2006; 72:3743.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/81\" class=\"nounderline abstract_t\">Aubron C, Poirel L, Fortineau N, et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 2005; 11:254.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/82\" class=\"nounderline abstract_t\">Gij&oacute;n D, Curiao T, Baquero F, et al. Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir in hospitalized and nonhospitalized patients. J Clin Microbiol 2012; 50:1558.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/83\" class=\"nounderline abstract_t\">Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol 2006; 44:3139.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/84\" class=\"nounderline abstract_t\">Yan JJ, Ko WC, Tsai SH, et al. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J Clin Microbiol 2001; 39:4433.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/85\" class=\"nounderline abstract_t\">Yan JJ, Hsueh PR, Ko WC, et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45:2224.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/86\" class=\"nounderline abstract_t\">Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ. Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece. Genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. Diagn Microbiol Infect Dis 2004; 48:167.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/87\" class=\"nounderline abstract_t\">Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006; 12:1209.</a></li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA. \r\n\r\n</li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. June 2010 Update. Clinical and Laboratory Standards Institute, Wayne, PA</li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA. \r\n\r\n\r\n\r\n\r\n</li><li class=\"breakAll\">CLSI M100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet http://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/CephalosporinandAztreonamBreakpointRevisionFactSheet/CephalosporinAztreonamBreakpointFactSheet.pdf (Accessed on January 26, 2011).</li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/92\" class=\"nounderline abstract_t\">Cornaglia G, Akova M, Amicosante G, et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29:380.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/93\" class=\"nounderline abstract_t\">Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/94\" class=\"nounderline abstract_t\">Carvalhaes CG, Pic&atilde;o RC, Nicoletti AG, et al. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 2010; 65:249.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/95\" class=\"nounderline abstract_t\">Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol 2012; 50:477.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/96\" class=\"nounderline abstract_t\">Wang P, Chen S, Guo Y, et al. Occurrence of false positive results for the detection of carbapenemases in carbapenemase-negative Escherichia coli and Klebsiella pneumoniae isolates. PLoS One 2011; 6:e26356.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/97\" class=\"nounderline abstract_t\">Vrioni G, Daniil I, Voulgari E, et al. Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Clin Microbiol 2012; 50:1841.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/98\" class=\"nounderline abstract_t\">Yan JJ, Wu JJ, Tsai SH, Chuang CL. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 2004; 49:5.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/99\" class=\"nounderline abstract_t\">Pic&atilde;o RC, Andrade SS, Nicoletti AG, et al. Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 2008; 46:2028.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/100\" class=\"nounderline abstract_t\">Girlich D, Halimi D, Zambardi G, Nordmann P. Evaluation of Etest&reg; strips for detection of KPC and metallo-carbapenemases in Enterobacteriaceae. Diagn Microbiol Infect Dis 2013; 77:200.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/101\" class=\"nounderline abstract_t\">Lee SH, Jeong SH, Lee KJ. Evolution of TEM beta--lactamase genes identified by PCR with newly designed primers in Korean clinical isolates. Clin Microbiol Infect 2001; 7:98.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/102\" class=\"nounderline abstract_t\">Lee K, Lim YS, Yong D, et al. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003; 41:4623.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/103\" class=\"nounderline abstract_t\">Pitout JD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43:3129.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/104\" class=\"nounderline abstract_t\">Galani I, Rekatsina PD, Hatzaki D, et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 2008; 61:548.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/105\" class=\"nounderline abstract_t\">Dod&eacute;mont M, De Mendon&ccedil;a R, Nonhoff C, et al. Performance of the Verigene Gram-negative blood culture assay for rapid detection of bacteria and resistance determinants. J Clin Microbiol 2014; 52:3085.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/106\" class=\"nounderline abstract_t\">Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial. J Clin Microbiol 2016; 54:687.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/107\" class=\"nounderline abstract_t\">Monteiro J, Widen RH, Pignatari AC, et al. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 2012; 67:906.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/108\" class=\"nounderline abstract_t\">Cuzon G, Naas T, Bogaerts P, et al. Evaluation of a DNA microarray for the rapid detection of extended-spectrum &beta;-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012; 67:1865.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/109\" class=\"nounderline abstract_t\">Stuart JC, Voets G, Scharringa J, et al. Detection of carbapenemase-producing Enterobacteriaceae with a commercial DNA microarray. J Med Microbiol 2012; 61:809.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/110\" class=\"nounderline abstract_t\">Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/111\" class=\"nounderline abstract_t\">Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46:847.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/112\" class=\"nounderline abstract_t\">Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol 2004; 42:5378.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/113\" class=\"nounderline abstract_t\">Tamma PD, Goodman KE, Harris AD, et al. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis 2017; 64:257.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/114\" class=\"nounderline abstract_t\">Satlin MJ, Chen L, Patel G, et al. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/115\" class=\"nounderline abstract_t\">Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother 2017; 72:668.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/116\" class=\"nounderline abstract_t\">Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/117\" class=\"nounderline abstract_t\">Shields RK, Clancy CJ, Press EG, Nguyen MH. Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2016; 60:3187.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/118\" class=\"nounderline abstract_t\">Bellais S, Mimoz O, L&eacute;otard S, et al. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:2032.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/119\" class=\"nounderline abstract_t\">Oliva A, Cipolla A, Gizzi F, et al. Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report. Medicine (Baltimore) 2016; 95:e2243.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/120\" class=\"nounderline abstract_t\">Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/121\" class=\"nounderline abstract_t\">van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/122\" class=\"nounderline abstract_t\">Wu G, Abraham T, Lee S. Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis 2016; 63:1147.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/123\" class=\"nounderline abstract_t\">Shields RK, Potoski BA, Haidar G, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis 2016; 63:1615.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/124\" class=\"nounderline abstract_t\">Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/125\" class=\"nounderline abstract_t\">Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/126\" class=\"nounderline abstract_t\">Shields RK, Chen L, Cheng S, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/127\" class=\"nounderline abstract_t\">Nath S, Moussavi F, Abraham D, et al. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2018; 73:431.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/128\" class=\"nounderline abstract_t\">Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis 2017; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/129\" class=\"nounderline abstract_t\">Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/130\" class=\"nounderline abstract_t\">Sabet M, Tarazi Z, Nolan T, et al. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018; 62.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/131\" class=\"nounderline abstract_t\">Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome &beta;-Lactam Resistance Conferred by Metallo-&beta;-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/132\" class=\"nounderline abstract_t\">Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2018; 73:542.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/133\" class=\"nounderline abstract_t\">Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018; 73:1104.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/134\" class=\"nounderline abstract_t\">Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011; 37:244.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/135\" class=\"nounderline abstract_t\">Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/136\" class=\"nounderline abstract_t\">Jernigan MG, Press EG, Nguyen MH, et al. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56:3395.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/137\" class=\"nounderline abstract_t\">Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/138\" class=\"nounderline abstract_t\">Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/139\" class=\"nounderline abstract_t\">Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013; 56:697.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/140\" class=\"nounderline abstract_t\">Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58:654.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/141\" class=\"nounderline abstract_t\">Guti&eacute;rrez-Guti&eacute;rrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17:726.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/142\" class=\"nounderline abstract_t\">Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/143\" class=\"nounderline abstract_t\">Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59:786.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/144\" class=\"nounderline abstract_t\">Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/145\" class=\"nounderline abstract_t\">Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009; 47:1611.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/146\" class=\"nounderline abstract_t\">Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19:E23.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/147\" class=\"nounderline abstract_t\">Giani T, Arena F, Vaggelli G, et al. Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant. J Clin Microbiol 2015; 53:3341.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/148\" class=\"nounderline abstract_t\">Rojas LJ, Salim M, Cober E, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clin Infect Dis 2017; 64:711.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/149\" class=\"nounderline abstract_t\">Han JH, Goldstein EJ, Wise J, et al. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals. Clin Infect Dis 2017; 64:839.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/150\" class=\"nounderline abstract_t\">Yu H, Qu F, Shan B, et al. Detection of the mcr-1 Colistin Resistance Gene in Carbapenem-Resistant Enterobacteriaceae from Different Hospitals in China. Antimicrob Agents Chemother 2016; 60:5033.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/151\" class=\"nounderline abstract_t\">Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37:415.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/152\" class=\"nounderline abstract_t\">Alexander BT, Marschall J, Tibbetts RJ, et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012; 34:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/153\" class=\"nounderline abstract_t\">Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16:184.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/154\" class=\"nounderline abstract_t\">Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/155\" class=\"nounderline abstract_t\">Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/156\" class=\"nounderline abstract_t\">Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 2014; 58:1684.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/157\" class=\"nounderline abstract_t\">Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:772.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/158\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/159\" class=\"nounderline abstract_t\">Banach DB, Bearman G, Barnden M, et al. Duration of Contact Precautions for Acute-Care Settings. Infect Control Hosp Epidemiol 2018; 39:127.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/160\" class=\"nounderline abstract_t\">Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/161\" class=\"nounderline abstract_t\">Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31:341.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/162\" class=\"nounderline abstract_t\">Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010; 31:620.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/163\" class=\"nounderline abstract_t\">Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis 2015; 60:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/164\" class=\"nounderline abstract_t\">Dortet L, Fusaro M, Naas T. Improvement of the Xpert Carba-R Kit for the Detection of Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 2016; 60:3832.</a></li><li><a href=\"https://www.uptodate.com/contents/overview-of-carbapenemase-producing-gram-negative-bacilli/abstract/165\" class=\"nounderline abstract_t\">Antonelli A, Arena F, Giani T, et al. Performance of the BD MAX&trade; instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis 2016; 86:30.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 471 Version 45.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLASSIFICATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Class A beta-lactamases</a><ul><li><a href=\"#H19876835\" id=\"outline-link-H19876835\">- Klebsiella pneumoniae carbapenemase (KPC)</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">Class B beta-lactamases</a><ul><li><a href=\"#H19877222\" id=\"outline-link-H19877222\">- New Delhi metallo-beta-lactamase (NDM-1)</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">Class D beta-lactamases</a></li></ul></li><li><a href=\"#H21045519\" id=\"outline-link-H21045519\">EPIDEMIOLOGY</a><ul><li><a href=\"#H92008072\" id=\"outline-link-H92008072\">Distribution</a><ul><li><a href=\"#H92008083\" id=\"outline-link-H92008083\">- Klebsiella pneumoniae carbapenemases</a></li><li><a href=\"#H92008117\" id=\"outline-link-H92008117\">- Metallo-beta-lactamases</a></li><li><a href=\"#H561110\" id=\"outline-link-H561110\">- Class D carbapenemases</a></li></ul></li><li><a href=\"#H21045526\" id=\"outline-link-H21045526\">Risk factors</a></li><li><a href=\"#H21045553\" id=\"outline-link-H21045553\">Transmission</a></li></ul></li><li><a href=\"#H92009070\" id=\"outline-link-H92009070\">DETECTION</a><ul><li><a href=\"#H92009113\" id=\"outline-link-H92009113\">Clinical laboratory testing</a></li><li><a href=\"#H92009120\" id=\"outline-link-H92009120\">Other phenotypic tests</a></li><li><a href=\"#H92009127\" id=\"outline-link-H92009127\">Direct genotypic identification</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">CLINICAL DISEASE</a></li><li><a href=\"#H17256132\" id=\"outline-link-H17256132\">SUSCEPTIBILITY TESTING</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">TREATMENT</a><ul><li><a href=\"#H1136483527\" id=\"outline-link-H1136483527\">Therapy for carbapenemase-producing Enterobacteriaceae</a><ul><li><a href=\"#H1155732076\" id=\"outline-link-H1155732076\">- Serious infections</a></li><li><a href=\"#H140542872\" id=\"outline-link-H140542872\">- Uncomplicated cystitis</a></li></ul></li><li><a href=\"#H1136483707\" id=\"outline-link-H1136483707\">Therapy for carbapenem-resistant A. baumannii and P. aeruginosa</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">INFECTION CONTROL</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/471|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/56259\" class=\"graphic graphic_table\">- Carbapenemase subgroups</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acinetobacter-infection-treatment-and-prevention\" class=\"medical medical_review\">Acinetobacter infection: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">Dosing and administration of parenteral aminoglycosides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscope-disinfection\" class=\"medical medical_review\">Endoscope disinfection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extended-spectrum-beta-lactamases\" class=\"medical medical_review\">Extended-spectrum beta-lactamases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=polymyxins-an-overview\" class=\"medical medical_review\">Polymyxins: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">Prolonged infusions of beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">Pseudomonas aeruginosa pneumonia</a></li></ul></div></div>","javascript":null}